Frazier Life Sciences Management, L.P. Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001892134

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 41 positions · Total reported value $4.59B · Top-10 concentration 73.6% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 22.7% · 6 new · 1 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q1 2026 → Q2 2026): +20.6% · vs SPY +5.8% · Prev Value $3.89B — last quarter positions weighted by this quarter price moves · ranking

In its Q2 2026 13F filing, Frazier Life Sciences Management, L.P. disclosed 41 equity positions with a combined reported value of $4.59B. The filing implies a focused portfolio: its ten largest positions account for 73.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were MIRM ($899.06M), NAMS ($613.03M), ERAS ($457.55M). By sector, the heaviest allocations are Health Care 99.8%, Materials 0.2%. Versus the prior quarter, allocation shifted toward Health Care (+2.6pp) and away from Other (-2.6pp).

Versus the prior quarter, Frazier Life Sciences Management, L.P. opened 6 new positions, trimmed 1 and fully exited 3, a turnover rate of 22.7% of positions. The portfolio's overlap with the prior quarter was 80% of names.

The largest new positions opened in Q2 2026 were PBLS ($52.57M), ACHV ($49.72M), DSGN ($26.19M).

Of the 3 positions fully exited versus the prior quarter, the largest were KALV ($99.87M), RVMD ($65.71M), AGIO ($42.49M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • PBLS PARABILIS MEDICINES INC · $52.57M
  • ACHV ACHIEVE LIFE SCIENCES INC · $49.72M
  • DSGN DESIGN THERAPEUTICS INC · $26.19M
  • STTK SHATTUCK LABS INC · $26.02M
  • KLRA KAILERA THERAPEUTICS INC · $24.23M
  • RLAY RELAY THERAPEUTICS INC · $19.00M

Fully Exited (vs previous quarter)

  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $99.87M
  • RVMD REVOLUTION MEDICINES INC COM · prev qtr: $65.71M
  • AGIO AGIOS PHARMACEUTICALS INC · prev qtr: $42.49M

Insider Transactions (Form 4)

Latest Frazier Life Sciences Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Frazier Life Sciences Management, L.P. is an SEC-registered 13F filer. As of Q2 2026 it reported 41 US equity positions with a combined value of $4.59B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 41 positions · $4.59B reported value (Q2 2026)
  • Top 10 holdings = 73.6% of reported value
  • Largest position: MIRM (MIRUM PHARMACEUTICALS INC) at 19.6%
  • Average position size: $112.00M

Sector Tilt

  • Health Care 99.8%
  • Materials 0.2%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 6 new, 8 added, 1 reduced, 3 exited
  • 26 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious stance, with a slight increase in positions, indicating a preference for stability and steady growth rather than aggressive expansion. The lack of significant changes in share counts and the majority of "hold" actions suggest a conservative approach aligned with the potential for gradual market gains. 2. Key Moves: - Additions: NewAmsterdam Pharma (NAMS) and Maze Therapeutics (MAZE) were added, with significant increases in share count for NAMS and a notable 10.2% increase for MAZE. - Reductions: There were no significant reductions in holdings. - Hold: The majority of positions were held steady, including Mirm (MIRM), MBX (MBX), ARQT (ARCUTIS), and others. 3. Portfolio Structure: - Passive vs. Active: The fund's approach seems more passive, as indicated by the "hold" actions on a majority of positions. - Sector Bias: The fund has a strong bias towards the healthcare sector, which is consistent with its name "Life Sciences." - Risk Appetite: The fund exhibits a moderate risk appetite, given the conservative approach and the emphasis on stability. 4. Per-Holding One-Liner: - MIRM (MIRUM PHARMACEUTICALS INC): Develops treatments for neurological and gastrointestinal disorders. - NAMS (NEWAMSTERDAM PHARMA COMPANY): Focuses on rare genetic disorders and cardiovascular diseases. - ERAS (ERASCA INC): Engaged in the development of therapies for metabolic and neurological diseases. - MBX (MBX BIOSCIENCES INC): Specializes in the development of treatments for rare and orphan diseases. - ARQT (ARCUTIS BIOTHERAPEUTICS INC): Develops treatments for dermatological conditions. - TRVI (TREVI THERAPEUTICS INC): Focuses on therapies for inflammatory and autoimmune diseases. - KRYS (KRYSTAL BIOTECH INC): Specializes in the development of treatments for genetic diseases. - MAZE (MAZE THERAPEUTICS INCORPORATED): Engaged in the development of therapies for cancer and genetic diseases. - PHAT (PHATHOM PHARMACEUTICALS INC): Focuses on treatments for cardiovascular and metabolic diseases. - PVLA (PALVELLA THERAPEUTICS INC NE): Develops therapies for oncology and other serious conditions. 5. One-Sentence Style Summary: Frazier Life Sciences Management maintained a conservative approach with a slight expansion in its healthcare-focused portfolio, reflecting a preference for stability and steady growth in the life sciences sector.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.8%
Materials 0.2%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 7.68M $899.06M 19.58%
19.58%
Hold
2 18.09M $613.03M 13.35%
13.35%
Add
3 24.98M $457.55M 9.96%
9.96%
Add
4 6.65M $367.19M 8.00%
8.00%
Hold
5 9.87M $258.91M 5.64%
5.64%
Hold
6 9.94M $185.37M 4.04%
4.04%
Hold
7 481.31K $178.89M 3.90%
3.90%
Hold
8 5.03M $150.18M 3.27%
3.27%
Add
9 12.47M $135.26M 2.95%
2.95%
Hold
10 882.40K $134.85M 2.94%
2.94%
Hold
11 1.55M $115.31M 2.51%
2.51%
Reduce
12 1.35M $99.09M 2.16%
2.16%
Hold
13 1.16M $98.81M 2.15%
2.15%
Hold
14 3.15M $70.03M 1.52%
1.52%
Hold
15 225.16K $60.05M 1.31%
1.31%
Add
16 9.72M $59.88M 1.30%
1.30%
Hold
17 1.92M $52.57M 1.15%
1.15%
New
18 7.10M $50.41M 1.10%
1.10%
Add
19 7.61M $49.72M 1.08%
1.08%
New
20 2.54M $46.83M 1.02%
1.02%
Hold
21 22.45M $46.69M 1.02%
1.02%
Add
22 728.64K $45.86M 1.00%
1.00%
Hold
23 4.01M $40.09M 0.87%
0.87%
Hold
24 700.65K $36.71M 0.80%
0.80%
Hold
25 1.44M $36.39M 0.79%
0.79%
Hold
26 1.90M $36.14M 0.79%
0.79%
Hold
27 6.60M $28.12M 0.61%
0.61%
Add
28 1.81M $26.19M 0.57%
0.57%
New
29 4.93M $26.06M 0.57%
0.57%
Hold
30 3.75M $26.02M 0.57%
0.57%
New
31 1.10M $24.23M 0.53%
0.53%
New
32 1.00M $24.20M 0.53%
0.53%
Hold
33 4.82M $22.46M 0.49%
0.49%
Add
34 1.02M $19.00M 0.41%
0.41%
New
35 2.63M $18.26M 0.40%
0.40%
Hold
36 484.78K $15.39M 0.34%
0.34%
Hold
37 2.29M $11.99M 0.26%
0.26%
Hold
38 500.33K $10.69M 0.23%
0.23%
Hold
39 4.45M $7.12M 0.15%
0.15%
Hold
40 422.50K $4.05M 0.09%
0.09%
Hold
41 1.95M $3.42M 0.07%
0.07%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q3) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q2)

P 90% R 90% F1 90% (modelled on 2026-Q1; 9/10 hit)

Historical Backtest (10 quarters)

Avg precision 88% · recall 88% · F1 88% · avg rank error 1.7 · Top-10 turnover 13%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 90% 90% 90% MIRM · HLVX · NAMS · KRYS · BBIO · RYTM · PHAT · PCVX · ALPN · VRNA NAMS · KRYS · MIRM · HLVX · ALPN · PHAT · BBIO · RYTM · ARQT · PCVX
2024-Q2 90% 90% 90% NAMS · KRYS · MIRM · HLVX · ALPN · PHAT · BBIO · RYTM · ARQT · PCVX NAMS · MIRM · KRYS · HLVX · PHAT · RYTM · BBIO · ARQT · IRON · PCVX
2024-Q3 80% 80% 80% NAMS · MIRM · KRYS · HLVX · PHAT · RYTM · BBIO · IRON · ARQT · PCVX MIRM · NAMS · PHAT · KRYS · MBX · RYTM · PCVX · VRNA · BBIO · IRON
2024-Q4 80% 80% 80% MIRM · NAMS · PHAT · KRYS · MBX · RYTM · VRNA · PCVX · IRON · BBIO NAMS · MIRM · VRNA · KRYS · ARQT · IRON · MBX · RYTM · BBIO · TARS
2025-Q1 80% 80% 80% NAMS · MIRM · VRNA · ARQT · KRYS · IRON · MBX · BBIO · RYTM · TARS NAMS · MIRM · VRNA · ARQT · BBIO · KRYS · IRON · TARS · TRVI · PHAT
2025-Q2 90% 90% 90% NAMS · MIRM · VRNA · ARQT · BBIO · KRYS · IRON · TARS · TRVI · PHAT MIRM · VRNA · NAMS · BBIO · ARQT · PHAT · KRYS · IRON · MBX · TARS
2025-Q3 100% 100% 100% MIRM · VRNA · NAMS · BBIO · ARQT · PHAT · KRYS · IRON · MBX · MAZE MIRM · NAMS · VRNA · BBIO · ARQT · PHAT · KRYS · MAZE · MBX · IRON
2025-Q4 90% 90% 90% MIRM · NAMS · VRNA · BBIO · ARQT · PHAT · MAZE · KRYS · MBX · TRVI NAMS · MIRM · ARQT · BBIO · MBX · PHAT · MAZE · TRVI · KRYS · IRON
2026-Q1 90% 90% 90% NAMS · MIRM · ARQT · BBIO · MBX · PHAT · MAZE · TRVI · KRYS · IRON MIRM · NAMS · ERAS · BBIO · ARQT · MBX · PHAT · MAZE · KRYS · TRVI
2026-Q2 ★ 90% 90% 90% MIRM · NAMS · ERAS · BBIO · ARQT · MBX · PHAT · MAZE · KRYS · TRVI MIRM · NAMS · ERAS · MBX · ARQT · TRVI · KRYS · MAZE · PHAT · PVLA

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did Frazier Life Sciences Management, L.P. buy in 2026-Q2?

In its 2026-Q2 13F filing, Frazier Life Sciences Management, L.P. reported 41 equity positions worth $4.59B in aggregate; its largest disclosed positions were MIRM ($899.06M), NAMS ($613.03M), ERAS ($457.55M).

How large is Frazier Life Sciences Management, L.P.'s portfolio?

Frazier Life Sciences Management, L.P. reported $4.59B of long equity holdings across 41 positions as of 2026-Q2. Top-10 holdings account for 73.6% of reported value.

What is Frazier Life Sciences Management, L.P.'s investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/frazier-life-sciences-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →